OncoTricks

A lambda clone, and a PSA without a testosterone, Oct 19, 2026

A lambda clone with numb feet, swollen legs and painful breasts

If you remember one thingA lambda M-protein with a neuropathy is POEMS until plasma VEGF and CT or PET/CT of the bones say otherwise.

Where to look

P Polyneuropathyascending, weakness over numbness O Organomegalyliver, spleen, nodes, Castleman E Endocrinopathytestosterone first; thyroid alone: no M Lambda M-proteinsmall, often missed on SPEP S Skindark, thick, hairy; red spots λ P O E M S 1 2 VEGF 3 leaks legs, belly, pleura, eye swells nerves
1
Fluid. Capillary leak: legs, belly, pleura, optic disc. The early deaths are this phenotype, refractory ascites and effusions, median 2.5 years from diagnosis (Lee 2025).
2
Bone. Sclerotic lesions. Whole-body CT bone windows and/or PET/CT; CT often shows more than FDG uptake, which is variable (Dispenzieri 2026). One lesion means radiation.
3
VEGF. Plasma over 200 pg/mL, specificity 95%, sensitivity 68% (D'Souza 2011); serum over 1920 pg/mL, specificity 98%, sensitivity 73% (Dispenzieri 2026). Normal does not exclude; follow trends.

The acronym names the findings; 1, 2 and 3 close the diagnosis.

Ask at every MGUS visit

Four questions1. Numb or weak feet, tripping, trouble on stairs?
2. Swollen legs or belly, fluid on a chest film?
3. Platelets or hemoglobin drifting up rather than down?
4. Libido, breasts, darker or thicker skin, new body hair?

The myeloma screen is negative by design.Small clone; high platelets or hemoglobin in half; creatinine 1.5 or above in only 6%; SPEP positive in 24 to 54%, immunofixation in 85% (Dispenzieri 2019, 2026).

Not amyloid

POEMS nerveAscending, symmetric, sensorimotor, demyelinating; slowing worse in intermediate than distal segments; motor predominant; pain in 10 to 15%. Usually mislabeled chronic inflammatory demyelinating polyneuropathy (CIDP); immunoglobulin and plasma exchange fail (Dispenzieri 2026).
Amyloid nerveAxonal, length-dependent; painful small-fiber loss early, autonomic failure, orthostatic hypotension. Nerve conduction may be normal early. NT-proBNP and troponin stage the heart, not the nerve.

Both are lambda. Nerve conduction and the cardiac markers pick the workup.If the M-protein was never sent, it was never excluded.

Decide in clinic

1. Lambda M-protein and a neuropathy?
yes
Stop calling it MGUS, order the POEMS setPlasma VEGF; whole-body CT bone windows or PET/CT; testosterone, LH, FSH, estradiol, prolactin, TSH, cortisol, HbA1c; fundoscopy; echo; lambda-stained marrow; nerve conduction; 24-hour urine.
then
2. VEGF high or sclerotic lesion?No: MGUS with neuropathy. Normal VEGF does not exclude POEMS; repeat if fluid, platelets or endocrine findings accumulate. Painful, autonomic, axonal neuropathy goes to fat pad and cardiac markers.
yes
It is POEMS. Count the lesionsNeuropathy, clone, one major and one minor criterion make the diagnosis (Dispenzieri 2026). Castleman disease on node biopsy is the third major.
then
3. One or two lesions, marrow clean?
yes
Radiation to the lesionClinical response 47%, 4-year survival 97% (Humeniuk 2013). Follow symptoms, M-protein and VEGF over 6 to 12 months; nerve recovery lags 6 months (Dispenzieri 2026).
or
4. Diffuse lesions or a marrow clone?
yes
Lenalidomide-dexamethasone or autologous transplantTransplant: 5-year overall survival 94% (D'Souza 2012). Lenalidomide-dexamethasone when transplant is not an option; low-dose melphalan-dexamethasone is the older alternative (Li 2011).
and
5. Neuropathy already disabling?Thalidomide and bortezomib carry a risk of worsening it; in a 69-patient bortezomib-dexamethasone series 46% reached complete hematologic response and 2 worsened (Dispenzieri 2026). Steroids temporize.

Ask the man with numb feet and an M-spike about his libido and his breasts.

Sources

Retrieved from PubMed, read on Oct 19, 2026; every figure re-checked against the primary text the same day.

  1. Dispenzieri A. POEMS syndrome: 2026 update on diagnosis, risk-stratification, and management. Am J Hematol 2026. doi:10.1002/ajh.70438
  2. Dispenzieri A. POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019. doi:10.1002/ajh.25495
  3. D'Souza A, Hayman SR, Buadi F, et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood 2011. doi:10.1182/blood-2011-06-362392
  4. D'Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome. Blood 2012. doi:10.1182/blood-2012-04-423178
  5. Humeniuk MS, Gertz MA, Lacy MQ, et al. Outcomes of patients with POEMS syndrome treated initially with radiation. Blood 2013. doi:10.1182/blood-2013-03-487025
  6. Li J, Zhang W, Jiao L, et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood 2011. doi:10.1182/blood-2010-12-328112
  7. Lee K, Kourelis T, Tschautscher M, et al. Capillary leak phenotype as a major cause of death in patients with POEMS syndrome. Leukemia 2025. doi:10.1038/s41375-024-02489-z

PSA 340 after six months of nothing

If you remember one thingNo testosterone, no verdict. PSA 340 after a gap is progression; the resistance label waits for the testosterone in the same tube.

The fork

Bone metastases, multiple sites. PSA 340. ADT plus docetaxel, six months off. Spine, legs. PSA, testosterone, one tube. PSMA PET. Germline and somatic testing. 1 TESTOSTERONE 2 200 ng/dL Hormone sensitive Restart ADT, antagonist Add AR pathway inhibitor 3 under 50 Castration resistant AR pathway inhibitor first Then change class
1
Before any drug. Ask the cord compression questions first and examine spine and legs. Draw PSA and testosterone from the same tube. PSMA PET restages the disease and, if he proves resistant later, documents the avidity lutetium requires (VISION). Send germline and somatic testing if never sent.
2
Testosterone 200. The resistance label was never earned; he is still hormone sensitive. After short ADT, half recover above 50 by about 5 months (Nascimento 2025). Degarelix castrates 96% by day 3 (Klotz 2008); relugolix 56% by day 4 (HERO); leuprolide needs bicalutamide cover. AR pathway inhibitor after docetaxel: a guideline option on subgroup evidence (ARCHES rPFS HR 0.53). Recheck at 8 weeks.
3
Testosterone under 50. Progression now has a definition (Scher 2016): PSA 25% and 2 ng/mL above nadir, confirmed after 3 weeks, or 2 new bone lesions confirmed by 2 more. Docetaxel already used, no inhibitor yet: inhibitor first, PARP combination per mutation, then change class. The second tree carries it.

Document the six months as a lapse.SWOG 9346: intermittent ADT in metastatic disease, median survival 5.1 vs 5.8 years, HR 1.10, non-inferiority not shown (Hussain 2013).

Decide in clinic

Any leg weakness or saddle numbnessMRI of the whole spine within 24 hours, dexamethasone now, then radiation oncology and spine surgery assess him before the PET (Patchell 2005).

2Testosterone 200

1. Testosterone 200 ng/dL after six months off?
yes
Hormone sensitive. Restart ADT, antagonist preferredDegarelix castrates 96% by day 3 (Klotz 2008); relugolix sustains castration in 96.7% vs 88.8% with leuprolide (HERO). Leuprolide alone needs bicalutamide for the flare.
then
2. Castrate now and never given an inhibitor?
yes
Add darolutamide, apalutamide or enzalutamideARASENS and PEACE-1 gave the inhibitor with docetaxel; after docetaxel the evidence is subgroup only (ARCHES rPFS HR 0.53, OS unproven). Abiraterone if comorbidities allow. Denosumab 60 mg every 6 months. PSA and testosterone at 8 weeks.

3Testosterone under 50

1. Confirmed progression with testosterone under 50?
yes
Castration resistant. AR pathway inhibitor firstEnzalutamide 160 mg daily or abiraterone 1,000 mg plus prednisone. Olaparib plus abiraterone only for BRCA (PROpel); talazoparib plus enzalutamide for HRR mutations (TALAPRO-2). Denosumab 120 mg monthly.
then
2. Confirmed progression on the inhibitor?
yes
Change class (CARD). Both options need marrowPET avid and VISION minimums (creatinine clearance 50, hemoglobin 9, platelets 100, neutrophils 1,500): lutetium 7.4 GBq every 6 weeks, 4 to 6 cycles. Otherwise cabazitaxel 20 mg/m2 (PROSELICA).
then
3. Progressing again after the class change?Radium-223 for painful bone-only disease (OS HR 0.70): 50 kBq/kg every 4 weeks, six doses; ALSYMPCA excluded visceral metastases and nodes over 3 cm. Pembrolizumab if MSI-high or mismatch repair deficient. Trial at every step.

Progression within 12 months on the first inhibitor: cabazitaxel beats a second one (CARD).

Sources

Retrieved from PubMed, read on Oct 20, 2026; every figure re-checked against the primary text the same day.

  1. Scher HI, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016. doi:10.1200/JCO.2015.64.2702
  2. Nascimento B, et al. Testosterone recovery after androgen deprivation therapy. J Sex Med 2025. doi:10.1093/jsxmed/qdaf164
  3. Klotz L, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008. doi:10.1111/j.1464-410X.2008.08183.x
  4. Shore ND, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer (HERO). N Engl J Med 2020. doi:10.1056/NEJMoa2004325
  5. Smith MR, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer (ARASENS). N Engl J Med 2022. doi:10.1056/NEJMoa2119115
  6. Fizazi K, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1). Lancet 2022. doi:10.1016/S0140-6736(22)00367-1
  7. Armstrong AJ, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019. doi:10.1200/JCO.19.00799
  8. Armstrong AJ, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer (ARCHES final analysis). J Clin Oncol 2022. doi:10.1200/JCO.22.00193
  9. Smith MR, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009. doi:10.1056/NEJMoa0809003
  10. Hussain M, et al. Intermittent versus continuous androgen deprivation in prostate cancer (SWOG 9346). N Engl J Med 2013. doi:10.1056/NEJMoa1212299
  11. Patchell RA, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer. Lancet 2005. doi:10.1016/S0140-6736(05)66954-1
  12. Fizazi K, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer. Lancet 2011. doi:10.1016/S0140-6736(10)62344-6
  13. Saad F, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel final analysis). Lancet Oncol 2023. doi:10.1016/S1470-2045(23)00382-0
  14. Agarwal N, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2). Lancet 2023. doi:10.1016/S0140-6736(23)01055-3
  15. de Wit R, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer (CARD). N Engl J Med 2019. doi:10.1056/NEJMoa1911206
  16. Sartor O, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer (VISION). N Engl J Med 2021. doi:10.1056/NEJMoa2107322
  17. Eisenberger M, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer (PROSELICA). J Clin Oncol 2017. doi:10.1200/JCO.2016.72.1076
  18. Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer (ALSYMPCA). N Engl J Med 2013. doi:10.1056/NEJMoa1213755

Abiraterone and the three lutamides

If you remember one thingAbiraterone shuts the factory; enzalutamide, apalutamide and darolutamide jam the receptor. In every setting on this page, all four sit on top of a castrate testosterone.

Concepts first

THE THREE SETTINGS, IN THE ORDER THEY HAPPEN Hormone sensitive metastatic (mHSPC) TESTOSTERONE normal; ADT starts now IMAGING metastases seen THE QUESTION what to add to ADT high volume: visceral or 4+ bone Castration resistant non-metastatic (nmCRPC, M0) TESTOSTERONE under 50, on ADT IMAGING CT and bone scan clean PSA doubling in 10 months PSMA PET usually sees more Castration resistant metastatic (mCRPC) TESTOSTERONE under 50 IMAGING new or growing lesions PSA 25% and 2 above nadir the lethal phase WHAT THE TRIALS MEASURE MFS time to a metastasison CT or bone scan rPFS time to growthon imaging, or death OS time to deaththe one that counts HR 0.70 30% fewer eventsover time, not deaths
ADTAndrogen deprivation therapy. LHRH agonist (leuprolide), antagonist (degarelix, relugolix), or orchiectomy. Removes testicular testosterone.
ARPIAndrogen receptor pathway inhibitor. Abiraterone blocks synthesis; a lutamide blocks the receptor. Removes what ADT leaves.

Where each drug acts

PituitaryLH Testis90% of testosterone Adrenaladrenal androgens Tumor itselfintracrine synthesis ADT blocks LH CYP17 androgen synthesis ABIRATERONE 1 block here and ACTH pushes mineralocorticoids up: prednisone T, DHT prostate cancer cell AR nucleus AR gene targets PSA, growth ENZALUTAMIDE, APALUTAMIDE, DAROLUTAMIDE 2 binding, entry into the nucleus, binding to DNA
1
Abiraterone. Blocks CYP17 in testis, adrenal and tumor, so androgens stop being made. The block also lowers cortisol, ACTH rises and mineralocorticoids climb: hypertension, low potassium, fluid. That is why it comes with prednisone (5 mg daily in hormone-sensitive disease, 5 mg twice daily in castration-resistant disease). Liver tests every 2 weeks for 3 months, then monthly. Empty stomach: a meal raises exposure 5 to 10 fold.
2
The three lutamides. Bind the androgen receptor harder than bicalutamide, keep it out of the nucleus and off the DNA, with no agonist effect. Enzalutamide and apalutamide cross into the brain (fatigue, falls, seizures) and induce CYP3A4 (interactions). Darolutamide barely enters the brain and induces almost nothing, but it raises rosuvastatin about 5 fold (BCRP); it is taken with food, 600 mg twice daily.

The trials that put each drug on the shelf

Three settings, three columns; on a phone, slide the table sideways.

DrugNon-metastatic CRPC
on ADT, testosterone under 50, PSA rising, nothing on CT and bone scan
Hormone-sensitive metastaticCastration-resistant metastatic
Abiraterone
1,000 mg + prednisone
no trialLATITUDE (high risk): OS 53.3 vs 36.5 mo, HR 0.66
STAMPEDE arm G: OS HR 0.61 in metastatic patients
PEACE-1 (with docetaxel): OS HR 0.82; 0.75 in the docetaxel group
COU-AA-302 (before chemo): OS 34.7 vs 30.3 mo, HR 0.81
COU-AA-301 (after docetaxel): OS 15.8 vs 11.2 mo, HR 0.74
Enzalutamide
160 mg daily
PROSPER: MFS 36.6 vs 14.7 mo, HR 0.29; OS HR 0.73ARCHES: rPFS HR 0.39; OS HR 0.66
ENZAMET: OS HR 0.70 (5 years)
PREVAIL (before chemo): OS 35.3 vs 31.3 mo, HR 0.77
AFFIRM (after docetaxel): OS 18.4 vs 13.6 mo, HR 0.63
Apalutamide
240 mg daily
SPARTAN: MFS 40.5 vs 16.2 mo, HR 0.28; OS HR 0.78TITAN: OS HR 0.65 (final); rPFS HR 0.48not approved
Darolutamide
600 mg twice daily
ARAMIS: MFS 40.4 vs 18.4 mo, HR 0.41; OS HR 0.69ARASENS (with docetaxel): OS HR 0.68
ARANOTE (without docetaxel): rPFS HR 0.54
not approved

Every box is a comparison against ADT, or ADT plus docetaxel, alone. No phase 3 has put one of the four against another.All placebo-controlled except STAMPEDE, PEACE-1 and ENZAMET, which were open label (ENZAMET against a first-generation antiandrogen). The one randomized sequencing study, phase 2, favored abiraterone first and enzalutamide second (Khalaf 2019). MFS: metastasis-free survival. OS: overall survival. rPFS: radiographic progression-free survival. HR: hazard ratio.

Choose the pill

1. Castration resistant and never had one?
yes
Abiraterone or enzalutamideThe only two approved in metastatic castration-resistant disease. Apalutamide and darolutamide are not labeled here.
or
2. Hormone sensitive, starting ADT?
yes
Any of the four; the comorbidities chooseWith docetaxel, the two with a dedicated triplet trial: darolutamide (ARASENS) or abiraterone (PEACE-1). Without: abiraterone, enzalutamide, apalutamide or darolutamide.
then
3. Uncontrolled diabetes, heart failure, liver disease, low potassium?
yes
Not abirateronePrednisone and mineralocorticoid excess make each of these worse.
then
4. Seizures, falls, cognitive decline, or a long drug list?
yes
Not enzalutamide or apalutamideDarolutamide: no excess seizures over placebo in ARAMIS, and seizure history was not an exclusion; no meaningful CYP induction, but check the statin. Apalutamide adds rash in a quarter and hypothyroidism in 8%.
and
5. Whatever you pick, the testosterone stays under 50The LHRH agonist or antagonist continues. Blood pressure, potassium and liver tests on abiraterone; falls and fatigue on the lutamides; bone density on all, a bone agent by setting.

A second lutamide after the first fails is a change of brand.After docetaxel and one inhibitor, cabazitaxel beat the second inhibitor (CARD, de Wit 2019).

Sources

Retrieved from PubMed, read on Oct 20, 2026.

  1. Fizazi K, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis. Lancet Oncol 2019. doi:10.1016/S1470-2045(19)30082-8
  2. James ND, et al. Abiraterone for prostate cancer not previously treated with hormone therapy (STAMPEDE). N Engl J Med 2017. doi:10.1056/NEJMoa1702900
  3. Ryan CJ, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis. Lancet Oncol 2015. doi:10.1016/S1470-2045(14)71205-7
  4. Fizazi K, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012. doi:10.1016/S1470-2045(12)70379-0
  5. Hussain M, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer (PROSPER). N Engl J Med 2018. doi:10.1056/NEJMoa1800536
  6. Armstrong AJ, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer (ARCHES). J Clin Oncol 2022. doi:10.1200/JCO.22.00193
  7. Sweeney CJ, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol 2023. doi:10.1016/S1470-2045(23)00063-3
  8. Beer TM, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol 2017. doi:10.1016/j.eururo.2016.07.032
  9. Scher HI, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy (AFFIRM). N Engl J Med 2012. doi:10.1056/NEJMoa1207506
  10. Smith MR, et al. Apalutamide and overall survival in prostate cancer (SPARTAN final analysis). Eur Urol 2021. doi:10.1016/j.eururo.2020.08.011
  11. Chi KN, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 2021. doi:10.1200/JCO.20.03488
  12. Fizazi K, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide (ARAMIS). N Engl J Med 2020. doi:10.1056/NEJMoa2001342
  13. Smith MR, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer (ARASENS). N Engl J Med 2022. doi:10.1056/NEJMoa2119115
  14. Saad F, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol 2024. doi:10.1200/JCO-24-01798
  15. Fizazi K, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1). Lancet 2022. doi:10.1016/S0140-6736(22)00367-1
  16. Sternberg CN, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer (PROSPER). N Engl J Med 2020. doi:10.1056/NEJMoa2003892
  17. Armstrong AJ, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019. doi:10.1200/JCO.19.00799
  18. Smith MR, et al. Apalutamide treatment and metastasis-free survival in prostate cancer (SPARTAN). N Engl J Med 2018. doi:10.1056/NEJMoa1715546
  19. Chi KN, et al. Apalutamide for metastatic, castration-sensitive prostate cancer (TITAN). N Engl J Med 2019. doi:10.1056/NEJMoa1903307
  20. Fizazi K, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer (ARAMIS). N Engl J Med 2019. doi:10.1056/NEJMoa1815671
  21. Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009. doi:10.1126/science.1168175
  22. Moilanen AM, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 2015. doi:10.1038/srep12007
  23. Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate. J Clin Oncol 2008. doi:10.1200/JCO.2007.15.9749
  24. Khalaf DJ, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 2019. doi:10.1016/S1470-2045(19)30688-6
  25. de Wit R, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer (CARD). N Engl J Med 2019. doi:10.1056/NEJMoa1911206